Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piromelatine in Mild Dementia Due to Alzheimer's Disease
NCT05267535Phase 3Terminated
- Sponsor
- Neurim Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of Piromelatine in Alzheimer's disease (AD), sponsored by Neurim Pharmaceuticals. Started Jun 2022; status: terminated.
02
Drugs
Piromelatine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05267535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267535.